ARWR · Arrowhead Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio
$65.45
-0.80 (-1.21%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$9.36B
Shares
141.25M
Volume · Sep 30
1.74M
Avg daily vol (3M)
1.92M
Arrowhead Pharmaceuticals, Inc. Earnings Call Transcripts
Quarterly earnings calls for Arrowhead Pharmaceuticals, Inc. (ARWR), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼17.5%
$31.57M
−$85.51M
'22 Q4
22-11-28
▲127.9%
$62.55M
−$41.33M
'23 Q1
22-12-31
▼3.6%
$146.27M
$48.67M
'23 Q2
23-05-02
▼51.2%
$15.82M
−$102.95M
'23 Q3
23-08-07
▼49%
$16.10M
−$109.68M
'23 Q4
23-11-29
▼94.3%
$3.55M
−$132.86M
'24 Q1
24-02-06
▼100%
$
−$125.30M
'24 Q2
24-05-09
▼100%
$
−$170.79M
'24 Q3
24-08-08
▼100%
$
−$170.54M
'24 Q4
24-11-26
▼29.6%
$2.50M
−$173.09M
'25 Q1
25-02-10
·
$542.71M
$370.44M
'25 Q2
25-05-12
·
$27.77M
−$175.24M
'25 Q3
25-08-07
·
$256.47M
−$23.75M
'25 Q4
25-11-25
▲10461.3%
$264.03M
$30.81M
'26 Q1
26-02-05
▼86.4%
$73.74M
−$132.73M
'26 Q2
26-05-07
LATEST
▲171%
$75.25M
−$194.28M
'26 Q3
26-08-04
Conference
Investor event
2026-09-16
Arrowhead Pharmaceuticals, Inc. (ARWR) September 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
Arrowhead Pharmaceuticals, Inc. (ARWR) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-08-04
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript
Confident tone
SHASTA Phase 3 results in SHTG
FCS launch / commercial momentum
Priority Review Voucher / regulatory acceleration
Revenue
$75.25M
▲ 171% YoY Diluted EPS
$-1.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-10
Arrowhead Pharmaceuticals, Inc. (ARWR) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Arrowhead Pharmaceuticals, Inc. (ARWR) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-05-07
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Confident tone
Commercial launch of Redemplo (FCS)
Pipeline breadth and innovation
Shasta-3/4 Phase 3 readout in SHTG
Revenue
$73.74M
▼ 86.4% YoY Diluted EPS
$-0.93
▼ 133.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-02-05
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Confident tone
Redempla launch and commercialization
Mixed hyperlipidemia / Aero-RPA
Caution on early launch and data interpretation
Revenue
$264.03M
▲ 10461.3% YoY Diluted EPS
$0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-11-25
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript
Confident tone
Rodemplo FDA approval and launch
Leadership transition
Shasta Phase III studies
Revenue
$256.47M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-08-07
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript
Confident tone
Plozasiran FCS approval and SHTG program
Zodasiran HoFH Phase III
Sarepta partnership
Revenue
$27.77M
Diluted EPS
$-1.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-05-12
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript
Confident tone
Plozasiran (FCS) launch and regulatory
Obesity programs (INHBE / ALK7)
CNS and BBB platform
Revenue
$542.71M
Diluted EPS
$2.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-02-10
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript
Confident tone
Plozasiran commercial launch and value proposition
Zodasiran HoFH Phase III
Obesity pipeline (ARO-IoN-HPE, ARO-ALK7)
Revenue
$2.50M
▼ 29.6% YoY Diluted EPS
$-1.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-11-26
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript
Confident tone
Sarepta licensing and collaboration deal
Wholly-owned cardiometabolic pipeline focus
Pulmonary platform partnering
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-08-08
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2024 Earnings Call Transcript
Confident tone
Plozasiran Commercial Opportunity
Phase 3 PALISADE Study
Earlier-Stage Pipeline (Obesity, Lung, Kidney)
Revenue
$
▼ 100% YoY Diluted EPS
$-1.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-05-09
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript
Confident tone
Cardiometabolic focus and pipeline value
Obesity and metabolic disease expansion
Plozasiran FCS approval and commercial launch
Revenue
$
▼ 100% YoY Diluted EPS
$-1.02
▼ 326.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-02-06
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2024 Earnings Call Transcript
Confident tone
Plozasiran / FCS Phase 3
Zodasiran / ANGPTL3
Pipeline breadth and partnerships
Revenue
$3.55M
▼ 94.3% YoY Diluted EPS
$-1.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-11-29
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2023 Earnings Call Transcript
Revenue
$16.10M*
▼ 49% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-08-07
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2023 Earnings Call Transcript
Revenue
$15.82M
▼ 51.2% YoY Diluted EPS
$-0.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-05-02
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2023 Earnings Call Transcript
Revenue
$146.27M
▼ 3.6% YoY Diluted EPS
$0.45
▲ 9.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-12-31
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2023 Earnings Call Transcript
Revenue
$62.55M
▲ 127.9% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-11-28
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2022 Earnings Call Transcript
Revenue
$31.57M*
▼ 17.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-08-04
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2022 Earnings Call Transcript
Revenue
$32.41M
▼ 29.4% YoY Diluted EPS
$-0.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-05-10
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2022 Earnings Call Transcript
Revenue
$151.81M
▲ 362.7% YoY Diluted EPS
$0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-02-02
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2022 Earnings Call Transcript
Revenue
$27.44M
▲ 28.8% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-11-22
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2021 Earnings Call Transcript
Revenue
$38.28M*
▲ 401.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-08-05
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2021 Earnings Call Transcript
Revenue
$45.89M
▲ 67.6% YoY Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-05-04
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2021 Earnings Call Transcript
Revenue
$32.81M
▲ 39.4% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-02-04
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2021 Earnings Call Transcript
Revenue
$21.30M
▼ 27.7% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-11-23
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2020 Earnings Call Transcript
Revenue
$7.63M
▼ 82.4% YoY Diluted EPS
$-0.48
▼ 500% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-08-05
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2020 Earnings Call Transcript
Revenue
$27.38M
▼ 35.9% YoY Diluted EPS
$-0.13
▼ 161.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-05-07
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2020 Earnings Call Transcript
Revenue
$23.53M
▼ 51.1% YoY Diluted EPS
$-0.20
▼ 183.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-02-05
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2020 Earnings Call Transcript
Revenue
$29.45M
▼ 15% YoY Diluted EPS
$-0.03
▼ 123.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–31 of 31 earnings calls
Key facts
CIK
879407
CUSIP
04280A100
13F (30d)
12 filings
12 filers
Visit website
Investor relations